Automated microanalysis of oxcarbazepine and its monohydroxy and transdiol metabolites in plasma by liquid chromatography

Rouan, Marie-Claude; M, Decherf; Clanche, V. Le; Lecaillon, J.B.; Godbillon, J.

doi:10.1016/0378-4347(94)00217-7

Cited by 37 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, some HPLC methods with ultra-violet [17][18][19][24][25][26][27][28][29][30][31][32][33][34] or mass spectrometry [10,11,35,36] detection for determining CBZ and/or OXCBZ in biological fluids (plasma, urine) have been published. Some of them involved both the quantitation of CBZ or OXCBZ and their main metabolites (CBZ-EP, 10-OH-CBZ, DiOH-CBZ [19,24,[26][27][28][29][30][31]33,34]. Other methods allow to quantify either CBZ, CBZ-EP, 10-OH-CBZ, DiOH-CBZ and the 9-acridan [25,32], or the hydroxylated compounds (2-hydroxycarbamazepine (2-OH-CBZ); 3-OH-CBZ) [18].…”

Section: Introductionmentioning

confidence: 99%

Liquid chromatography–electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma

Breton

Cociglio

Bressolle

et al. 2005

Journal of Chromatography B

139

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Liquid chromatography–electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma

Breton

Cociglio

Bressolle

et al. 2005

Journal of Chromatography B

139

View full text Add to dashboard Cite

“…Over the years, several chromatographic methods for OXC and racemic licarbazepine determination have been developed (Noirfalise and Collinge, 1983;Menge et al, 1987;Elyas et al, 1990;Rouan et al, 1994;Pienimaki et al, 1995;Souppart et al, 2001;Levert et al, 2002;Mandrioli et al, 2003;Franceschi and Furlanut, 2005;Lanckmans et al, 2006). However, only three chiral HPLC assays have been validated to determine S-and R-LC enantiomers, in which a very expensive column and mobile phase were employed (Flesch et al, 1992;Pichini et al, 1995;Volosov et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Enantioselective HPLC‐UV method for determination of eslicarbazepine acetate (BIA 2‐093) and its metabolites in human plasma

Alves

Figueiredo

Castel‐Branco

et al. 2007

Biomedical Chromatography

View full text Add to dashboard Cite

Determination of eslicarbazepine acetate ABSTRACT: Eslicarbazepine acetate (BIA 2-093) is a novel central nervous system drug undergoing clinical phase III trials for epilepsy and phase II trials for bipolar disorder. A simple and reliable chiral reversed-phase HPLC-UV method was developed and validated for the simultaneous determination of eslicarbazepine acetate, oxcarbazepine, S-licarbazepine and R-licarbazepine in human plasma. The analytes and internal standard were extracted from plasma by a solid-phase extraction using Waters Oasis ® HLB cartridges. Chromatographic separation was achieved by isocratic elution with water-methanol (88:12, v/v), at a flow rate of 0.7 mL/min, on a LichroCART 250-4 ChiraDex (β-cyclodextrin, 5 μm) column at 30°C. All compounds were detected at 225 nm. Calibration curves were linear over the range 0.4 -8 μg/mL for eslicarbazepine acetate and oxcarbazepine, and 0.4 -80 μg/ mL for each licarbazepine enantiomer. The overall intra-and interday precision and accuracy did not exceed 15%. Mean relative recoveries varied from 94.00 to 102.23% and the limit of quantification of the assay was 0.4 μg/mL for all compounds. This method seems to be a useful tool for clinical research and therapeutic drug monitoring of eslicarbazepine acetate and its metabolites S-licarbazepine, R-licarbazepine and oxcarbazepine.

show abstract

“…Most of the analytical methods were published for the analysis of OXC in plasma samples by liquid chromatography-mass spectrometry (LC-MS) and high-performance liquid chromatography (HPLC) methods [6][7][8][9][10][11][12][13][14]. Very few HPLC and UV spectrophotometric methods were reported for the estimation of OXC in bulk and formulations [15][16][17].…”

Section: Introductionmentioning

confidence: 99%

RP-HPLC-PDA method development and validation for the estimation of oxcarbazepine in bulk and formulations

Raghavi¹,

Sindhura²,

Prashanthi³

et al. 2013

Acta Chromatographica

View full text Add to dashboard Cite

Summary.A simple, precise, rapid, and accurate liquid chromatography-mass spectrometry (LC-MS) compatible reversed phase high-performance liquid chromatography-photodiode array detection (RP-HPLC-PDA) method has been developed and validated for the estimation of oxcarbazepine (OXC) in bulk and tablet formulations. The chromatographic separation was achieved on Phenomenex C 18 column (150 mm × 4.6 mm, 5.0 μm particle size) using the mobile phase comprising methanol-formic acid (0.02% v/v in water) in the ratio of 50:50 (v/v) at a flow rate of 1 mL min −1 , and OXC was eluted at 6.4 min. Quantification and linearity were achieved at 229 nm over the concentration range of 10-50 μg mL −1 , and the mean percentage of assay was found to be 100.03. The method was validated for specificity, linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ), stability, and robustness as per the International Conference on Harmonisation (ICH) guidelines and it is suitable to be employed in quality control.

show abstract

Automated microanalysis of oxcarbazepine and its monohydroxy and transdiol metabolites in plasma by liquid chromatography

Cited by 37 publications

References 12 publications

Liquid chromatography–electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma

Liquid chromatography–electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma

Enantioselective HPLC‐UV method for determination of eslicarbazepine acetate (BIA 2‐093) and its metabolites in human plasma

RP-HPLC-PDA method development and validation for the estimation of oxcarbazepine in bulk and formulations

Contact Info

Product

Resources

About